Kerdsirichairat Tossapol, Shin Eun Ji
Digestive Disease Center, Bumrungrad International Hospital, Bangkok 10120, Thailand.
Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, United States.
World J Gastrointest Endosc. 2022 Apr 16;14(4):191-204. doi: 10.4253/wjge.v14.i4.191.
There has been a growing interest in developing endoscopic ultrasound (EUS)-guided interventions for pancreatic cancer, some of which have become standard of care. There are two main factors that drive these advancements to facilitate treatment of patients with pancreatic cancer, ranging from direct locoregional therapy to palliation of symptoms related to inoperable pancreatic cancer. Firstly, an upper EUS has the capability to access the entire pancreas-lesions in the pancreatic head and uncinate process can be accessed from the duodenum, and lesions in the pancreatic body and tail can be accessed from the stomach. Secondly, there has been a robust development of devices that allow through-the-needle interventions, such as placement of fiducial markers, brachytherapy, intratumoral injection, gastroenterostomy creation, and ablation. While these techniques are rapidly emerging, data from a multicenter randomized controlled trial for some procedures are awaited prior to their adoption in clinical settings.
人们对开发用于胰腺癌的内镜超声(EUS)引导下的干预措施的兴趣日益浓厚,其中一些已成为标准治疗方法。有两个主要因素推动了这些进展,以促进胰腺癌患者的治疗,从直接局部区域治疗到缓解与无法手术切除的胰腺癌相关的症状。首先,上消化道EUS能够检查整个胰腺——胰头和钩突的病变可从十二指肠进入,胰体和胰尾的病变可从胃进入。其次,允许通过针进行干预的设备有了强劲发展,如放置基准标记、近距离放射治疗、瘤内注射、胃肠造口术创建和消融。虽然这些技术正在迅速兴起,但在临床应用之前,还需要等待一些程序的多中心随机对照试验数据。